241 related articles for article (PubMed ID: 32626713)
21. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells.
Qian LW; Mizumoto K; Inadome N; Nagai E; Sato N; Matsumoto K; Nakamura T; Tanaka M
Int J Cancer; 2003 May; 104(5):542-9. PubMed ID: 12594808
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic Stellate Cells Facilitate Perineural Invasion of Pancreatic Cancer via HGF/c-Met Pathway.
Nan L; Qin T; Xiao Y; Qian W; Li J; Wang Z; Ma J; Ma Q; Wu Z
Cell Transplant; 2019; 28(9-10):1289-1298. PubMed ID: 31161784
[TBL] [Abstract][Full Text] [Related]
23. Promise and challenges on the horizon of MET-targeted cancer therapeutics.
Zhang YW
World J Biol Chem; 2015 May; 6(2):16-27. PubMed ID: 26009700
[TBL] [Abstract][Full Text] [Related]
24. Ezrin mediates both HGF/Met autocrine and non-autocrine signaling-induced metastasis in melanoma.
Huang L; Qin Y; Zuo Q; Bhatnagar K; Xiong J; Merlino G; Yu Y
Int J Cancer; 2018 Apr; 142(8):1652-1663. PubMed ID: 29210059
[TBL] [Abstract][Full Text] [Related]
25. The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer.
Parizadeh SM; Jafarzadeh-Esfehani R; Fazilat-Panah D; Hassanian SM; Shahidsales S; Khazaei M; Parizadeh SMR; Ghayour-Mobarhan M; Ferns GA; Avan A
IUBMB Life; 2019 Jul; 71(7):802-811. PubMed ID: 31116909
[TBL] [Abstract][Full Text] [Related]
26. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
27. Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells.
Hung CM; Kuo DH; Chou CH; Su YC; Ho CT; Way TD
J Agric Food Chem; 2011 Sep; 59(17):9683-90. PubMed ID: 21806057
[TBL] [Abstract][Full Text] [Related]
28. Hepatocyte growth factor in physiology and infectious diseases.
Imamura R; Matsumoto K
Cytokine; 2017 Oct; 98():97-106. PubMed ID: 28094206
[TBL] [Abstract][Full Text] [Related]
29. The HGF-met signaling axis: emerging themes and targets of inhibition.
Steffan JJ; Coleman DT; Cardelli JA
Curr Protein Pept Sci; 2011 Feb; 12(1):12-22. PubMed ID: 21190524
[TBL] [Abstract][Full Text] [Related]
30. Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer.
Sylvester PW
Clin Transl Med; 2014 Dec; 3(1):30. PubMed ID: 26932375
[TBL] [Abstract][Full Text] [Related]
31. Hepatocyte Growth Factor/C-Met Axis in Thyroid Cancer: From Diagnostic Biomarker to Therapeutic Target.
Trovato M; Campennì A; Giovinazzo S; Siracusa M; Ruggeri RM
Biomark Insights; 2017; 12():1177271917701126. PubMed ID: 28469401
[TBL] [Abstract][Full Text] [Related]
32. HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation.
Spina A; De Pasquale V; Cerulo G; Cocchiaro P; Della Morte R; Avallone L; Pavone LM
Biomedicines; 2015 Jan; 3(1):71-88. PubMed ID: 28536400
[TBL] [Abstract][Full Text] [Related]
33. Clinical and prognostic value of the C-Met/HGF signaling pathway in cervical cancer.
Boromand N; Hasanzadeh M; ShahidSales S; Farazestanian M; Gharib M; Fiuji H; Behboodi N; Ghobadi N; Hassanian SM; Ferns GA; Avan A
J Cell Physiol; 2018 Jun; 233(6):4490-4496. PubMed ID: 29058790
[TBL] [Abstract][Full Text] [Related]
34. IFITM3 promotes malignant progression, cancer stemness and chemoresistance of gastric cancer by targeting MET/AKT/FOXO3/c-MYC axis.
Chu PY; Huang WC; Tung SL; Tsai CY; Chen CJ; Liu YC; Lee CW; Lin YH; Lin HY; Chen CY; Yeh CT; Lin KH; Chi HC
Cell Biosci; 2022 Aug; 12(1):124. PubMed ID: 35941699
[TBL] [Abstract][Full Text] [Related]
35. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
36. Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement.
Huang X; Li E; Shen H; Wang X; Tang T; Zhang X; Xu J; Tang Z; Guo C; Bai X; Liang T
Front Cell Dev Biol; 2020; 8():152. PubMed ID: 32435640
[TBL] [Abstract][Full Text] [Related]
37. Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.
Zhang Y; Jain RK; Zhu M
Biomedicines; 2015 Mar; 3(1):149-181. PubMed ID: 28536405
[TBL] [Abstract][Full Text] [Related]
38. Up-regulation of hepatocyte growth factor receptor: an amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure.
Liu Y; Tolbert EM; Lin L; Thursby MA; Sun AM; Nakamura T; Dworkin LD
Kidney Int; 1999 Feb; 55(2):442-53. PubMed ID: 9987069
[TBL] [Abstract][Full Text] [Related]
39. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
40. Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases.
Whang YM; Jung SP; Kim MK; Chang IH; Park SI
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
